| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1470-2045(17)30605-8 |
| P698 | PubMed publication ID | 29033099 |
| P50 | author | Karim Fizazi | Q73569107 |
| Fred Saad | Q88065306 | ||
| Tomasz M Beer | Q90949746 | ||
| P2093 | author name string | Florence Joly | |
| Vsevolod Matveev | |||
| Kim N Chi | |||
| Sebastien J Hotte | |||
| Aude Fléchon | |||
| Gwenaelle Gravis | |||
| Brent Blumenstein | |||
| Boris Alekseev | |||
| Cindy A Jacobs | |||
| Patricia S Stewart | |||
| Zafar Malik | |||
| P2860 | cites work | Clusterin is an ATP-independent chaperone with very broad substrate specificity that stabilizes stressed proteins in a folding-competent state | Q24290651 |
| Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells | Q24294824 | ||
| Clusterin inhibits apoptosis by interacting with activated Bax | Q24316499 | ||
| Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data | Q26771537 | ||
| Targeting the adaptive molecular landscape of castration-resistant prostate cancer | Q27022821 | ||
| Prostate cancer: ESMO Consensus Conference Guidelines 2012 | Q27022847 | ||
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| The mutational landscape of lethal castration-resistant prostate cancer | Q29614634 | ||
| Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 | Q29615661 | ||
| Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer | Q29616123 | ||
| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer | Q29616218 | ||
| Alpha emitter radium-223 and survival in metastatic prostate cancer | Q29617472 | ||
| Increased survival with enzalutamide in prostate cancer after chemotherapy | Q29617511 | ||
| Abiraterone and increased survival in metastatic prostate cancer | Q29617512 | ||
| Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial | Q29620155 | ||
| Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins | Q30244818 | ||
| Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 | Q30277291 | ||
| Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group | Q33566395 | ||
| Enzalutamide in metastatic prostate cancer before chemotherapy | Q34422206 | ||
| Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. | Q35879087 | ||
| Management of advanced prostate cancer after first-line chemotherapy | Q36309722 | ||
| Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. | Q38202357 | ||
| European cancer mortality predictions for the year 2016 with focus on leukaemias | Q38915866 | ||
| Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies | Q38994189 | ||
| Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. | Q39165788 | ||
| Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. | Q39262037 | ||
| Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy | Q40003248 | ||
| Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen. | Q42685237 | ||
| Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. | Q42928474 | ||
| The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer | Q43059748 | ||
| Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 | Q45957143 | ||
| Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer | Q46427019 | ||
| A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer | Q46689589 | ||
| Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents | Q47931535 | ||
| Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. | Q51102220 | ||
| Clusterin Has Chaperone-like Activity Similar to That of Small Heat Shock Proteins | Q57639622 | ||
| P433 | issue | 11 | |
| P921 | main subject | docetaxel | Q420436 |
| P304 | page(s) | 1532-1542 | |
| P577 | publication date | 2017-10-09 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, internation | |
| P478 | volume | 18 |
| Q64268339 | A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer |
| Q90729992 | Abiraterone vs. docetaxel for metastatic hormone-sensitive prostate cancer: A microsimulation model |
| Q88912942 | Alternative splicing and cancer metastasis: prognostic and therapeutic applications |
| Q53681746 | Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). |
| Q64247127 | Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled Analysis |
| Q93336018 | Bone marrow-derived fibroblasts are a functionally distinct stromal cell population in breast cancer |
| Q64087689 | Clusterin in Alzheimer's Disease: Mechanisms, Genetics, and Lessons From Other Pathologies |
| Q57286596 | Glucocorticoids Induce Stress Oncoproteins Associated with Therapy-Resistance in African American and European American Prostate Cancer Cells |
| Q90293688 | Incidence of fatigue and low-dose corticosteroid use in prostate cancer patients receiving systemic treatment: a meta-analysis of randomized controlled trials |
| Q64257298 | Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer |
| Q52677688 | Periostin antisense oligonucleotide suppresses bleomycin-induced formation of a lung premetastatic niche for melanoma. |
| Q92451337 | Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer |
| Q50109412 | Prostate cancer: No benefit of combining custirsen with cabazitaxel |
| Q55080589 | Secretory Clusterin Mediates Oxaliplatin Resistance via the Gadd45a/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma. |
| Q91142539 | Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis |
| Q92702584 | The Multiple Roles and Therapeutic Potential of Molecular Chaperones in Prostate Cancer |
| Q99566100 | The efficacy and safety of abiraterone acetate in patients with high-risk prostate cancer: a meta-analysis based on six randomized control trials |
Search more.